We are live on
!
Find out more
GCM
Glenview Capital Management Portfolio holdings
AUM
$3.98B
1-Year Est. Return
20.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.71%
1 Year Est. Return
+20.52%
3 Year Est. Return
+68.18%
5 Year Est. Return
+87.14%
10 Year Est. Return
+400.35%
AUM
$4.94B
AUM Growth
+$247M
(+5.3%)
Cap. Flow
+$219M
Cap. Flow
% of AUM
4.43%
Top 10 Holdings %
Top 10 Hldgs %
54.49%
Holding
66
New
9
Increased
26
Reduced
20
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FISV
Fiserv Inc
FISV
|
+$166M |
| 2 |
Cigna
CI
|
+$114M |
| 3 |
US Foods
USFD
|
+$102M |
| 4 |
DXC Technology
DXC
|
+$84.5M |
| 5 |
Aptiv
APTV
|
+$74.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$164M |
| 2 |
Willis Towers Watson
WTW
|
+$86.2M |
| 3 |
Bausch Health
BHC
|
+$79.3M |
| 4 |
Tenet Healthcare
THC
|
+$77.7M |
| 5 |
FMC
FMC
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.81% |
| 2 | Technology | 16.28% |
| 3 | Consumer Discretionary | 10.31% |
| 4 | Industrials | 9.41% |
| 5 | Materials | 6.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELL
51
DELISTED
PhenomeX Inc. Common Stock
CELL
| $8.48M | 0.17% |
+1,193,332
| New | +$9.87M |
|
52
Ouster
OUST
$2.92B
| $5.08M | 0.1% |
112,898
-7,300
| -6% | -$269K |
|
|
OHPAU
53
DELISTED
Orion Acquisition Corp. Unit
OHPAU
| $4.76M | 0.1% |
485,001
| – | – |
|
54
Rapid Micro Biosystems
RPID
$86.2M
| $4.52M | 0.09% |
+665,807
| New | +$4.9M |
|
55
Evolus
EOLS
$501M
| $4.43M | 0.09% |
394,810
+983
| +0.2% | +$8.38K |
|
56
Evolv Technologies
EVLV
$1.1B
| $3.97M | 0.08% |
1,499,461
+750,000
| +100% | +$2.45M |
|
57
Hyperfine
HYPR
$101M
| $3.46M | 0.07% |
977,000
-23,000
| -2% | -$95K |
|
|
ENDP
58
DELISTED
Endo International plc
ENDP
| $2.6M | 0.05% |
1,126,435
-1,054,804
| -48% | -$3.09M |
|
59
Digimarc Corp
DMRC
$178M
| $1.98M | 0.04% |
75,000
| – | – |
|
60
Cytek Biosciences
CTKB
$546M
| $597K | 0.01% |
+55,413
| New | +$748K |
|
61
Amgen
AMGN
$222B
| – | – |
-134,645
| Closed | -$30.3M |
|
|
DNB
62
DELISTED
Dun & Bradstreet
DNB
| – | – |
-734,595
| Closed | -$15.1M |
|
63
PUT
Alphabet (Google) Class A
GOOGL
$4.33T
| – | – |
-240,000
| Closed | -$34.8M |
|
64
Humana
HUM
$46.2B
| – | – |
-54,978
| Closed | -$25.5M |
|
|
65
CALL
McKesson
MCK
$101B
| – | – |
-160,000
| Closed | -$39.8M |
|
|
66
Willis Towers Watson
WTW
$32B
| – | – |
-362,996
| Closed | -$86.2M |
|
Similar funds
MAM
USCWA
LWCA
JSW
AS
BWA
BCP
MIM
Glenview Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Glenview Capital Management held 66 positions worth $4.94B, up 5.3% from $4.69B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Glenview Capital Management deployed $219M of net new capital in Q1 2022, opening 9 new positions and adding to 26 existing holdings. Its largest new stake was Valvoline: 1,744,570 shares worth $55.1M.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 58% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was McKesson, an estimated $164M trimmed.
- Glenview Capital Management's largest Q1 2022 buy was Valvoline: 1,744,570 shares worth $55.1M.
- Glenview Capital Management added most to Fiserv Inc in Q1 2022, an estimated $166M increase.
- Glenview Capital Management's biggest Q1 2022 reduction was McKesson, cutting an estimated $164M.
- Glenview Capital Management fully exited Willis Towers Watson in Q1 2022, selling an estimated $86.2M.
- Glenview Capital Management's ten largest holdings make up 54% of its $4.94B portfolio in Q1 2022.
- Glenview Capital Management opened 9 new positions and closed 6 in Q1 2022.
- Glenview Capital Management's portfolio value rose 5.3% quarter-over-quarter to $4.94B.
Based on Glenview Capital Management's 13F filing for Q1 2022, filed 16 May 2022.